TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

European journal of molecular biology and biochemistry

Volume 6, Issue 1, 2019
Mcmed International
European journal of molecular biology and biochemistry
Issn
2348 - 2192 (Print), 2348 - 2206 (Online)
Frequency
bi-annual
Email
editorejmbb@mcmed.us
Journal Home page
http://mcmed.us/journal/ejmbb
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
AFTER LUNG TRANSPLANTATION, HLA OR MICA ANTIBODIES ARE INDUCED IN IGM AND IGG CELLS
Author
Dr. K Amaranth Reddy*, Dr. Sivakumar
Email
Amaranth@gmail.com
keyword
Lung transplant, Anti-bodies, IgM, IgG, Immunosuppressive regimens
Abstract
End-stage lung disease patients can benefit from lung transplantation. AMR, however, poses a significant threat to the survival of long-term grafts. As part of the pathogenesis of AMR, HLA-specific antibodies and immunity to major histocompatibility complex class Irelated chain A antibodies are produced following lung transplantation. Our review summarizes the current knowledge about how IgM and IgG antibodies are induced after lung transplantation against HLA or MICA. Immunosuppressive regimens affect antibody production based on their choice and intensity. Low antibody titers and reduced AMR risk have been associated with higher doses of immunosuppressive medications, such as calcineurin inhibitors. A challenging aspect of immunosuppression is finding the right balance between infection risk and other adverse effects. As a diagnostic tool for identifying patients at risk of AMR, IgG and IgM antibodies to HLA and MICA have become crucial. The most commonly used methods for detecting antibodies are solid-phase assays and flow cytometry. Detecting antibody development early through serial monitoring allows therapeutic interventions to be guided. As a result, IgM and IgG antibodies against HLA or MICA are crucial for AMR development following lung transplantation. Optimising immunosuppressive regimens and transplant outcomes requires understanding the factors influencing antibody production. AMR needs to be mitigated through targeted therapies and further research is needed to understand the mechanisms of antibody induction
Download Broucher
Back to Top >>>>